Relation between uric acid and metabolic syndrome in subjects with cardiometabolic risk
Relação entre ácido úrico e síndrome metabólica em uma população com risco cardiometabólico

Hellen Abreu da Silva¹, Júlia Cristina Cardoso Carraro¹, Josefina Bressan¹, Helen Hermana Miranda Hermsdorff²

ABSTRACT
Objective: To identify possible relations between serum uric acid levels and metabolic syndrome and its components in a population with cardiometabolic risk. Methods: This cross-sectional study included 80 subjects (46 women), with mean age of 48±16 years, seen at the Cardiovascular Health Program. Results: The prevalence of hyperuricemia and metabolic syndrome was 6.3% and 47.1%, respectively. Uric acid level was significantly higher in individuals with metabolic syndrome (5.1±1.6mg/dL), as compared to those with no syndrome or with pre-syndrome (3.9±1.2 and 4.1±1.3mg/dL, respectively; p<0.05). The uric acid levels were significantly higher in men presenting abdominal obesity, and among women with abdominal obesity, lower HDL-c levels and higher blood pressure (p<0.05). Conclusion: Uric acid concentrations were positively related to the occurrence of metabolic syndrome and its components, and there were differences between genders. Our results indicate serum uric acid as a potential biomarker for patients with cardiometabolic risk.

Keywords: Uric acid; Obesity, abdominal; Metabolic diseases; Cardiovascular diseases/metabolism; Risk groups

INTRODUCTION
Cardiovascular diseases (CVD) are among the main causes of morbidity and mortality in the world. In Brazil, CVD are one of the most prevalent causes of death, accounting for 29.4% of all recorded deaths in a one-year period. The condition affects mainly men.

Several risk factors are associated with the development of CVD, including obesity, dyslipidemia, hypertension, diabetes mellitus and some lifestyle-related conditions, such as smoking, sedentary lifestyle, and atherogenic eating habits.

The metabolic syndrome (MS) represents a group of predisposing factors: abdominal obesity or central adiposity, dyslipidemia (hypertriglyceridemia and/or reduced high-density lipoprotein cholesterol – HDL-c), hyperglycemia or diabetes, and arterial hypertension.
or pre-hypertension. MS correlates directly with the development of CVD and diabetes.\(^{(4)}\) A systematic review based on 10 cross-sectional studies estimated the mean prevalence of MS in Brazil as 29.6%, ranging between 14.9 and 65.3% according to the study population.\(^{(5)}\)

In this context, attempts to establish diagnostic criteria for MS are based on the principle that these components may act in a synergistic or additive manner, augmenting the cardiometabolic risk.\(^{(6)}\) Krishnan and Sokolove\(^{(7)}\) proposed that uric acid (UA) level could be used as a marker for cardiovascular risk. However, a rational physiological base is needed to explain the relation between UA and cardiovascular risk and the development of appropriate therapies to treat changes in UA levels, since these potential associations still remain unproven.\(^{(8)}\)

Including UA as a variable to stratify cardiovascular risk may be interesting, because it is low-cost, easily-performed test, which is useful in clinical practice, especially for MS patients.\(^{(6,8-10)}\) However, few studies have investigated the predictive role of UA levels\(^{(6,8-10)}\) and studies that investigate the relation between UA and MS criteria in patients previously detected with cardiovascular risk are still scarce.

**OBJECTIVE**

To identify the potential relationship between serum concentrations of uric acid and metabolic syndrome and its components in a population at cardiometabolic risk.

**METHODS**

This is an observational, cross-sectional study using data from subjects followed up at the Cardiovascular Health Program from the *Universidade Federal de Viçosa* (PROCARDIO-UFV, acronym in Portuguese), from November 2012 to June 2013. Sample calculations were performed using the *OpenEpi* software,\(^{(11)}\) taking into account the total number of PROCARDIO users in 2012 (n=91), a confidence interval of 95%, an expected prevalence rate of 29.8% for MS,\(^{(12)}\) and a sampling error of 5%, which resulted in a minimum sample of 72 people. The inclusion criteria were the same as defined by PROCARDIO; subjects should be aged 20 years or more, be members of the staff/their dependents or students at the *Universidade Federal de Viçosa* (UFV), and show one or more of the following criteria: overweight or obesity, hypertriglyceridemia (≥150mg/dL); hypercholesterolemia (≥200mg/dL), low HDL-cholesterol (men <40mg/dL and women <50mg/dL), high LDL (≥130mg/dL), blood pressure (≥130/85mmHg) or diagnosed hypertension, fasting glucose (≥110mg/dL), *diabetes mellitus* diagnosed and/or medical referral related to some of the previously described metabolic changes.

This study was approved by the Human Research Ethics Committee of UFV (Of. Ref. nº 066/2012/CEPH), in June 27, 2012, in agreement with the principles of the Declaration of Helsinki; therefore, subjects who agreed to participate in the study signed the Informed Consent Form.

**Anthropometrics and body composition**

Body weight was measured on an electronic digital scale (Toledo 2098PP, São Bernardo do Campo, Brazil) with maximum capacity of 200kg and 50g precision. Height was determined using a stadiometer (Stanley,cmS, England), with maximum extension of 2m and precision of 0.5mm. Body mass index (BMI) was calculated and used to classify overweight and obesity, in agreement with the World Health Organization recommendations.\(^{(13)}\)

Waist circumference (WC) was measured at the umbilical scar. Abdominal obesity was classified based on WC values >102 and 88cm for men and women, respectively.\(^{(14)}\) To determine the percentage of total body fat, a bioelectric impedance equipment was used (Biodynamics 310 model, Washington, US).

**Blood pressure and serum metabolic markers**

Systolic and diastolic arterial blood pressure were measured with a mechanical mercury sphygmomanometer (BIC, São Paulo, Brazil), with approximations of 2mmHg, according to the technique described at the Sixth Brazilian Guidelines for Hypertension.\(^{(15)}\)

Biochemical analysis of fasting glucose, tryglycerides, total cholesterol and fractions, and UA were performed at the Clinical Analysis Laboratory of the Health Department - UFV, in agreement with their standardized protocols. Hyperuricemia was defined as >6 and 7mg/dL of UA for women and men, respectively.\(^{(16)}\)

**Definition of metabolic and pre-metabolic syndrome**

MS was diagnosed according to the guidelines of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (*Adult Treatment Panel III – ATP III*),\(^{(4)}\) in the presence of three or more of the following criteria: abdominal obesity according to waist circumference (>102cm for men and >88cm for women).
for women), hypertriglyceridemia (≥150mg/dL), low HDL-c (<40mg/dL for men and <50mg/dL for women), pre-hypertension or hypertension (≥130mmHg or ≥85mmHg) and fasting glucose (≥110mg/dL and/or diagnosed diabetes mellitus). Pre-MS was defined as the presence of two of these criteria.(17)

Other study variables
Sociodemographic variables (sex, age, and relation with UFV) and lifestyle variables (smoking and physical activity) were assessed with a specific questionnaire from PROCARDIO-UFV.

Former smokers were classified in the same group as smokers, separately from those who never smoked. Concerning physical activities, participants were classified as active if they had performed physical activities of moderate intensity for at least three months, and at least three times a week (~150 minutes/week). Others were classified as sedentary.

Statistical analysis
Data were given as mean±standard deviation (SD) or median (interquartile range) according to the normality of variables, which was tested with the Shapiro-Wilk test. The study sample was divided into two groups: low UA and high UA, defined by the median of each sex: 4.8mg/dL for men and 3.4mg/dL for women. Medians have been previously used as cutoff points; this is based on the validated method of distributing the population into risk groups in epidemiologic studies.(19)

To compare means between two groups, Student’s t test or Mann-Whitney test were used according to the data distribution, and χ² test to compare frequencies. To compare means between three groups, ANOVA variance test was used, followed by Tukey post hoc test. Variables that did not show normal distribution were previously transformed in log to apply ANOVA. Multivariate linear regression analyses were performed to assess the effect of UA concentrations on the prediction of the number of MS components, adjusting for confounding variables.

Statistical analyses were performed on the Statistical Package for the Social Sciences (SPSS) for Windows, version 17.0. Significance level was 5% for all hypotheses tested.

RESULTS
The study sample was composed by 80 subjects, predominantly female (n=46; 57.5%). Mean age was 48±16 years, and prevalence of hyperuricemia was 6.3% (n=5). Prevalences of 47.1% (n=33) of MS and 32.9% (n=23) of pre-MS were observed in the sample.

Interestingly, subjects with no MS or with pre-MS showed significantly lower UA levels as compared to those with MS (Figure 1). The frequency of subjects with high UA levels (≥4.8mg/dL for men and ≥3.4mg/dL for women) was higher for those with MS (Figure 2).

Subjects with high UA also showed higher BMI, WC, and total body fat, with no difference in sex, age, physical activity levels, and smoking status (Table 1).

Differences in results between sexes were observed when UA levels were assessed according to the presence of MS components. Therefore, UA concentrations were higher among men showing abdominal obesity, and there was an increasing trend with hypertriglyceridemia. Among women, those with abdominal obesity, low HDL-c levels and high blood pressure showed higher serum UA levels (Table 2).
Approximately 84% of subjects (n=67) were constant users of medication; 20% (n=16) were on glucose-lowering agents (oral or insulin), 46% (n=37) on antihypertensive drugs, and 58% (n=46) on lipid-lowering drugs (to reduce cholesterol and/or triglycerides). However, there was no difference in UA levels between subjects using medication or not (oral antidiabetic drugs, p=0.594; insulin, p=0.693; antihypertensive drugs, p=0.910; cholesterol-reducing drugs, p=0.303; and fibrates, p=0.08).

Finally, multiple linear regression analysis showed that UA predicted the number of MS components regardless of age, sex, and other confounding variables (Table 3).

### Table 3. Multiple linear regression analysis of uric acid level (mg/dL) as a predictor for number of metabolic syndrome components

| Component                        | β     | CI (95%)       | R²   | p value |
|----------------------------------|-------|----------------|------|---------|
| Simple regression                | 0.600 | (0.254; 0.947) | 0.149| 0.001   |
| Model 1*                         | 0.592 | (0.199; 0.984) | 0.239| <0.001  |
| Model 2**                        | 0.591 | (0.223; 0.948) | 0.116| 0.011   |

*Adjusted for sex and age; ** adjusted for physical activity and use of medication. 95% CI: 95% confidence interval.

### DISCUSSION

This study contributed to a better understanding of UA in relation to the clinical and metabolic variables in a population at cardiometabolic risk.

UA is an organic compound, endogenously produced by the liver in humans as a metabolite of purine. It is formed by adenosine, inosine, hypoxanthine, adenine and guanine, and it is the main hydrophilic antioxidant in the body.(20,21) Therefore, UA inhibits the action of free radicals on organic molecules, such as those present in cell membranes and genetic material.(22) However, the acute increase in UA level seems to be a protective factor against oxidative stress, and its chronic increase is associated with the risk of chronic, non-communicable diseases.(6,9)

In this context, the first relevant result of this study was the detection of higher UA levels in subjects showing MS when compared to those who did not. Our results are similar to those observed in previous cross-sectional studies.(9)

The prevalence of MS observed in this study surpassed that described in previous studies.(9,23) However, studies have shown prevalence rates of MS ranging from 8.0 to 70.7%, depending on the age group.(9) On the other hand, it is possible that the high rates...
observed in this study are due to the older age group of subjects, as well as to the fact that it is a population at cardiometabolic risk, directly related to the presence of the syndrome. Previous epidemiologic studies have also shown increased serum UA levels in adults with MS, as well as an association between increased UA levels and oxidative stress, endothelial dysfunction, inflammation, atherosclerosis, and increased risk of cardiovascular events. According to Rho et al., there is a strong association between UA and MS, which suggests that the former could be an independent contributor to the development of the condition. Some studies suggest that because UA is an effective antioxidant, the increase in this biomarker among subjects with MS might reflect a compensatory mechanism to the increased oxidative stress associated to MS.

Gagliardi et al. stated that UA levels are higher according to the number of MS components. This corroborates the results observed in this study, since subjects with pre-MS (two components) showed lower UA levels in relation to those with MS (three or more components). This relation can also be observed by the predicting effect of UA on the number of MS components even after adjustments; therefore, it represents a potential risk factor. Other studies have also shown an association between hyperuricemia and MS components – abdominal obesity, hypertension, dyslipidemia - kidney diseases, and CVD.

The association between UA and cardiometabolic risk factors seems to show differences between sexes, such as observed between other biomarkers and cardiometabolic risk, where women showed more noticeable effects. The results of this study confirm such hypothesis, since women showed significant differences in UA values when three MS components were observed, while men showed significant differences even in the presence of one single component.

BMI and total body fat, indicators of total adiposity; and WC, indicator of central adiposity, showed an association with UA levels. De Oliveira et al. observed that subjects with BMI ≥25kg/m² and lower muscle mass levels showed higher UA levels. The release of the hormone leptin is directly related to the degree of adiposity, and it seems to induce oxidative stress in endothelial cells, thus increasing UA levels. Besides, leptin and insulin resistance can reduce the renal excretion of UA.

The association between tryglycerides and UA observed in men was reported by other authors. One potential mechanism involved in this relation is the fact that tryglycerides synthesis requires more NADPH. Moreover, the synthesis of fatty acids in the liver is related to increased synthesis of purines, therefore speeding up the pace of UA production.

A significant relation between arterial hypertension and UA concentrations was identified in this study. These results were described in other studies, such as that by Barbosa et al., with a sample of 756 subjects, in which a direct association between blood pressure and UA was observed. The reduced excretion of UA is reported in patients with MS, and it seems to reflect changes in renal excretion of renal UA, secondary to the increased resorption of sodium by proximal tubules, mediated by hyperinsulinemia. Another plausible mechanism refers to the action of UA by inhibiting the bioavailability of nitric oxide, a powerful vasodilator.

This study showed an inverse association between HDL-c and UA levels. The same was observed by Barbosa et al. in a not hospitalized population. The relation between low HDL and high UA seems to be mediated by insulin resistance; that was confirmed by de Oliveira et al., who observed that the correlation between HDL and UA is lost after statistical adjustments by MS components.

This study had some limitations. First of all, this is a cross-sectional study, which only allows the analysis of variable associations, without time inferences. Although the sample calculations were adequate to guarantee power, studies with a population-based sample are still required. Other pieces of information, such as use of medication, habitual diet, drinking habits, and menopausal status could be assessed in future studies.

CONCLUSION

The uric acid levels were related to the presence of metabolic syndrome and its components, for which differences in sex were observed. Our results highlighted the importance of uric acid as a biomarker in patients at cardiometabolic risk as well as the need to reconsider the nutritional therapy of hyperuricemic patients considering the treatment of metabolic syndrome.

ACKNOWLEDGMENTS

To the study volunteers and to the team at the Nutrition Department, Health Division at UFV, for their
technical assistance, and for the volunteer trainees from PROCARDIO-UFV for their support in data collection. To the Culture and Extension Vice-president Office (PEC/UFV) for the university scholarship, and to the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) for the doctorate scholarship granted to HAS and JCCC, respectively. Finally, we thank Fundação Arthur Bernardes (Funarbe) for the grant Quality in Excellence Research for Young Researchers granted to HHMH.

REFERENCES

1. Borges CF, Busnello FM, Pellanda LC. Identificação de fatores de risco cardiovascular em pais/cuidadores de crianças cardiopatas. Arq Bras Cardiol. 2012;99(4):936-43.

2. Bressan J, Hermdosff HH, Zulet MA, Martínez JA. Impacto hormonal e inflamatório de diferentes composições dietéticas: ênfase em padrões alimentares e fatores dietéticos específicos. Arq Bras Endocrinol Metabol. 2009;53(5):572-81. Review.

3. Sposito AC, Caramelli B, Fonseca FA, Bertolami MC, Afiune Neto A, Souza AD, Lottenberg AM, Chacra AP, Falud AA, Laires-Vale AA, Carvalho AC, Duncan B, Geloneze B, Polanczyk C, Rodrigues Sobrinho CR, Scherr C, Karta C, Armacanjan D, Moriqui E, Saraiva F, Pichetti G, Xavier HT, Chaves H, Borges JL, Diament J, Guimarães J, Nicolau JC, dos Santos JE, de Lima JJ, Vieira JL, Novazzi JP, Faria Neto JR, Torres KP, Pinto Lda A, Bricarelo L, Bodanese LC, Intracosa L, Malachias MV, Ibar MC, Magalhães ME, Schmidt MI, Scartezini M, Nobre M, Foppa M, Forti NA, Berwanger O, Gebara OC, Coelho OR, Maranhão RC, dos Santos Filho RD, Costa RP, Barreto S, Kaiser S, Ibarra S, Carvalho Td, Martínez TL, Relvas WC, Salgado W. Sociedade Brasileira de Cardiologia. [IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology]. Arq Bras Cardiol. 2007;88 Suppl 1:2-19.

4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.

5. de Carvalho Vidigal F, Bressan J, Babio N, Salas-Salvadó J. Prevalence of cardiovascular risk in Brazil. Arq Bras Cardiol. 2009;53(5):572-81. Review.

6. Sposito AC, Caramelli B, Fonseca FA, Bertolami MC, Afiune Neto A, Souza AD, Lottenberg AM, Chacra AP, Falud AA, Laires-Vale AA, Carvalho AC, Duncan B, Geloneze B, Polanczyk C, Rodrigues Sobrinho CR, Scherr C, Karta C, Armacanjan D, Moriqui E, Saraiva F, Pichetti G, Xavier HT, Chaves H, Borges JL, Diament J, Guimarães J, Nicolau JC, dos Santos JE, de Lima JJ, Vieira JL, Novazzi JP, Faria Neto JR, Torres KP, Pinto Lda A, Bricarelo L, Bodanese LC, Intracosa L, Malachias MV, Ibar MC, Magalhães ME, Schmidt MI, Scartezini M, Nobre M, Foppa M, Forti NA, Berwanger O, Gebara OC, Coelho OR, Maranhão RC, dos Santos Filho RD, Costa RP, Barreto S, Kaiser S, Ibarra S, Carvalho Td, Martínez TL, Relvas WC, Salgado W. Sociedade Brasileira de Cardiologia. [IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology]. Arq Bras Cardiol. 2007;88 Suppl 1:2-19.

7. de Carvalho Vidigal F, Bressan J, Babio N, Salas-Salvadó J. Prevalence of metabolic syndrome in adult Brazilians; a systematic review. BMC Public Health. 2013;13:1198. Review.

8. Tsuchi SG, Liberopoulos EN, Mikhalidis DP, Athyros VG, Eliaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism. 2006;55(10):1293-301. Review.

9. Krishnan E, Sokolove J. Uric acid in heart disease: a new C-reactive protein? Curr Opin Rheumatol. 2011;23(2):174-7. Review. Erratum in: Curr Opin Rheumatol. 2011;23(4):410.

10. Barbosa MC, Brandão AA, Pozzan R, Magalhães ME, Campana EM, Fonseca FL, et al. Associação entre ácido único e variáveis de risco cardiovascular em uma população não hospitalar. Arq Bras Cardiol. 2011;96(3):212-8.

11. Serpa Neto A, Rossi FM, Valle LG, Teixeira G, Rossi M. Relation of uric acid with components of metabolic syndrome before and after roux-en-y gastric bypass in mobidly obese subject. Arq Bras Endocrinol Metabol. 2011;55(1):38-45.

12. Gagliardi AC, Miname MH, Santos RD. Uric acid: A marker of increased cardiovascular risk. Atherosclerosis. 2009, 202(1):11-7. Review.

13. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Versão. www.OpenEpi.com. [atualizado 2014/09/22, cited 2014 Oct 30].

14. Cavagnoni LC, Benserât M, Halpen A, Pierin AM. [Metabolic Syndrome in professional truck drivers who work on Highway BR-116 within the area of São Paulo City - Régis Bittencourt]. Arq Bras Endocrinol Metab. 2008;52(6):1015-23. Portuguese.

15. World Health Organization (WHO). BMI Classification, 2013. WHO [cited 2014 June 30]. Available from: apps.who.int/bmi/index.jsp?IntratoPage—intr_3.html

16. Sociedade Brasileira de Hipertensão; Sociedade Brasileira de Cardiologia; Sociedade Brasileira de Endocrinologia e Metabologia; Sociedade Brasileira de Diabetes. Sociedade Brasileira de Estudos da Obesidade. I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica. Arq Bras Cardiol. 2005;84 Suppl 1:3-28.

17. Vasques AC, Rosado LR, Rosado GP, Ribeiro Rld C, Franceschini Sdo C, Geloneze B, et al. [Predictive ability of anthropometric and body composition indicators in the identification of insulin resistance]. Arq Bras Endocrinol Metabol. 2009;53(1):72-9. Erratum in: Arq Bras Endocrinol Metabol. 2009;53(3):388. Portuguese.

18. Hochberg MC, Smolen JS, Weinblatt ME. Rheumatology. 3rd ed. New York: Mosby; 2003.

19. Yin Q, Chen X, Li L, Zhou R, Huang J, Yang D. Apolipoprotein B/apolipoprotein A1 ratio is a good predictive marker of metabolic syndrome and pre-metabolic syndrome in Chinese adolescent women with polycystic ovary syndrome. J Obstet Gynaecol Res. 2013;39(1):203-9.

20. Zivin AC, Elder MG, Lane S, Qi L, Vlahakis N, Hegele RA. Serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2005;177(1):289-97. Review.

21. Willett WC. Nutritional epidemiology. 2nd ed. New York: Oxford University Press; 1998.

22. Ross FD, Espeland MA, Haiman CA, Lieber MM, Willett WC, Hennekens CH, Polk BE. A1 ratio is a good predictive marker of metabolic syndrome and pre-metabolic syndrome in Chinese adolescent women with polycystic ovary syndrome. J Obstet Gynaecol Res. 2013;39(1):203-9.

23. Zivin AC, Elder MG, Lane S, Qi L, Vlahakis N, Hegele RA. Serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2005;177(1):289-97. Review.

24. Ross FD, Espeland MA, Haiman CA, Lieber MM, Willett WC, Hennekens CH, Polk BE. A1 ratio is a good predictive marker of metabolic syndrome and pre-metabolic syndrome in Chinese adolescent women with polycystic ovary syndrome. J Obstet Gynaecol Res. 2013;39(1):203-9.

25. Zivin AC, Elder MG, Lane S, Qi L, Vlahakis N, Hegele RA. Serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2005;177(1):289-97. Review.

26. Nieto FJ, Iribarren C, Gross MD, Comstocka GW, Cutler RG. Uric acid and metabolic syndrome: an active component or an innocent bystander? Metabolism. 2006;55(10):1293-301. Review.

27. Tsoul SG, Liberopoulos EN, Mikhalidis DP, Athyros VG, Eliaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism. 2006;55(10):1293-301. Review.

28. Krishnan E, Sokolove J. Uric acid in heart disease: a new C-reactive protein? Curr Opin Rheumatol. 2011;23(2):174-7. Review. Erratum in: Curr Opin Rheumatol. 2011;23(4):410.

29. Barbosa MC, Brandão AA, Pozzan R, Magalhães ME, Campana EM, Fonseca FL, et al. Associação entre ácido único e variáveis de risco cardiovascular em uma população não hospitalar. Arq Bras Cardiol. 2011;96(3):212-8.

30. Serpa Neto A, Rossi FM, Valle LG, Teixeira G, Rossi M. Relation of uric acid with components of metabolic syndrome before and after roux-en-y gastric bypass in mobidly obese subject. Arq Bras Endocrinol Metabol. 2011;55(1):38-45.

31. Gagliardi AC, Miname MH, Santos RD. Uric acid: A marker of increased cardiovascular risk. Atherosclerosis. 2009, 202(1):11-7. Review.
relationship between fasting serum uric acid and the insulin sensitivity index in a population-based sample of 380 young healthy Caucasians. Eur J Endocrinol. 1998;138(1):63-9.

30. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuño GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980;93(6):817-21.